JB Chemicals & Pharmaceuticals is keen to explore new opportunities in the world of metabolics and improve its own chronic contribution to be up to around 60% of its India business. With chronic holding 50% of its domestic sales, the move into diabetes – growing at little over 10% a year, valued at around $5bn to $6bn – would make an attractive market.
